Moffitt Cancer Center's planning and evaluation of research activities encompass 3 internal and 1 external advisory bodies, as well as ad hoc consultants as needed. Moffitt requests $75,000 to support a portion of these activities, including $70,000 in the category of Consultant Costs and $5,000 in the category of Other Expenses. All advisory bodies report to the Center Director. Each Associate Center Director meets at least monthly with the Center Director and together, they take a lead role in overseeing the planning and evaluation process. These advisory bodies have successfully guided the rapid growth of research over the past decade, and the requested support will continue to enhance these efforts. Moffitt's external advisory board, the Council of Scientific Advisors, reviews the Center's scientific progress in terms of the CCSG by evaluating the research programs, shared resources, scientific and institutional accomplishments, and future plans for sustaining and increasing research growth. It also evaluates the annual research accomplishments relative to the state mandate and reports its findings to the Center's Board of Directors and state officials. Ad hoc advisors advise Moffitt on refining strategic research areas, evaluating its methods, and suggest ways to better organize specific efforts. Moffitt also requests funds for the Center's annual Scientific Retreat. The all day event pulls together faculty, postdoctoral fellows, and students to showcase research from all areas (basic, population, clinical investigations, and translational) and includes an outside keynote speaker.
Moffitt's success relies on long-term strategic planning and evaluation and funds for this category are critical to Moffitt success. In particular, the recommendations of external advisors have been vital to strengthening the research enterprise.
|Chung, Brile; Stuge, Tor B; Murad, John P et al. (2014) Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep 8:871-82|
|Charbonneau, Bridget; Block, Matthew S; Bamlet, William R et al. (2014) Risk of ovarian cancer and the NF-*B pathway: genetic association with IL1A and TNFSF10. Cancer Res 74:852-61|
|Unrod, Marina; Simmons, Vani N; Sutton, Steven K et al. (2014) A randomized clinical trial of self-help intervention for smoking cessation: research design, interventions, and baseline data. Contemp Clin Trials 38:284-90|
|Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256|
|Padron, Eric; Yoder, Sean; Kunigal, Sateesh et al. (2014) ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123:3675-7|
|Hampras, Shalaka S; Viscidi, Raphael P; Helzlsouer, Kathy J et al. (2014) Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23:2591-6|
|Chen, Ning; Chon, Hye Sook; Xiong, Yin et al. (2014) Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep 31:376-83|
|Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna et al. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1|
|Carvalho, Renato S; Fernandes, Vanessa C; Nepomuceno, Thales C et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15:840-50|
|Rizwani, Wasia; Schaal, Courtney; Kunigal, Sateesh et al. (2014) Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 9:e100888|
Showing the most recent 10 out of 108 publications